Forte Biosciences Inc

NASDAQ:FBRXUnited States

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Contact Information

Headquarters

3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247

Phone

310-618-6994

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Paul Wagner

Chief Financial Officer

Antony Riley

Independent Director

Scott Brun

Independent Director

Stephen Doberstein

Independent Director

Barbara Finck